Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study

•A study of patient-reported ASM side effects in a multicenter observational study.•A total of 40 % (05 %CI 36–45) out of 406 participants reported side effects.•The number of ASMs and age were significant risk factors for side effects.•Side effects remain a clinical concern. Side effects is one of...

Full description

Saved in:
Bibliographic Details
Published in:Seizure (London, England) England), 2023-12, Vol.113, p.23-27
Main Authors: Zelano, Johan, Nika, Olha, Asztely, Fredrik, Larsson, David, Andersson, Klara, Andrén, Kerstin
Format: Article
Language:English
Subjects:
Epilepsy
Neurologi
Neurology
Side effects
Treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c398t-9fdc560eb3681a7568c4a941bf2d2a3a01a90cb51eec9b790bbf1a4383a8a58b3
container_end_page 27
container_issue
container_start_page 23
container_title Seizure (London, England)
container_volume 113
creator Zelano, Johan
Nika, Olha
Asztely, Fredrik
Larsson, David
Andersson, Klara
Andrén, Kerstin
description •A study of patient-reported ASM side effects in a multicenter observational study.•A total of 40 % (05 %CI 36–45) out of 406 participants reported side effects.•The number of ASMs and age were significant risk factors for side effects.•Side effects remain a clinical concern. Side effects is one of the major clinical problems in epilepsy care. We assessed the prevalence of ASM side effects in participants in a large regional multicenter observational study in western Sweden and aimed to identify risk factors and inventory the nature of side effects with different ASM regimes. Cross-sectional analysis of survey answers and clinical characteristics of 406 adult participants recruited to a regional observational study between December 2020 and March 2023. Half of the participants had been seizure free for one year. Second-generation or newer ASMs were the most common. A total of 164 (40 %, 95 %CI: 36–45) patients reported side effects. Patients reporting side effects were younger (median 41 vs 47 years, p = 0.015), had more frequently experienced a seizure in the last year (p = 0.02), and were more often on ASM polytherapy (p 
doi_str_mv 10.1016/j.seizure.2023.10.016
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_gup_ub_gu_se_330865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1059131123002819</els_id><sourcerecordid>2886937659</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-9fdc560eb3681a7568c4a941bf2d2a3a01a90cb51eec9b790bbf1a4383a8a58b3</originalsourceid><addsrcrecordid>eNqFkUuPEzEQhEcIxD7gJ4B85DLBHscT-4TQaoGVVgIJOFttuyc4mswMfmS1_Ho6StgrJ1vVn6vlqqZ5I_hKcNG_360yxj814arjnSRtReqz5lIo2bVdr_VzunNlWiGFuGiuct5xzs1ayJfNhdwYKaTqLpvDt4QHGHHyyGAKbIJCnmwe2AIl4lTahMucCgYal3jeyfYYoidgnliOARkOA_qSWZwYsO8PNM2_WMItATCyfR1LbD25YWK51PD4qnkxwJjx9fm8bn5-uv1x86W9__r57ubjfeul0aU1Q_Cq5-hkrwVsVK_9GugPbuhCBxK4AMO9UwLRG7cx3LlBwFpqCRqUdvK6aU---QGX6uyS4h7So50h2m1dLEnbajNaKbnuFfHvTvyS5t8Vc7H7mD2OI0w412w7rXsjN70yhKoT6tOcc8LhyVxwe6zI7uw5Lnus6CiTSu_enldURzE-vfrXCQEfTgBSMIeIyWYfjwWFmChkG-b4nxV_AWHDqKY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2886937659</pqid></control><display><type>article</type><title>Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Zelano, Johan ; Nika, Olha ; Asztely, Fredrik ; Larsson, David ; Andersson, Klara ; Andrén, Kerstin</creator><creatorcontrib>Zelano, Johan ; Nika, Olha ; Asztely, Fredrik ; Larsson, David ; Andersson, Klara ; Andrén, Kerstin</creatorcontrib><description>•A study of patient-reported ASM side effects in a multicenter observational study.•A total of 40 % (05 %CI 36–45) out of 406 participants reported side effects.•The number of ASMs and age were significant risk factors for side effects.•Side effects remain a clinical concern. Side effects is one of the major clinical problems in epilepsy care. We assessed the prevalence of ASM side effects in participants in a large regional multicenter observational study in western Sweden and aimed to identify risk factors and inventory the nature of side effects with different ASM regimes. Cross-sectional analysis of survey answers and clinical characteristics of 406 adult participants recruited to a regional observational study between December 2020 and March 2023. Half of the participants had been seizure free for one year. Second-generation or newer ASMs were the most common. A total of 164 (40 %, 95 %CI: 36–45) patients reported side effects. Patients reporting side effects were younger (median 41 vs 47 years, p = 0.015), had more frequently experienced a seizure in the last year (p = 0.02), and were more often on ASM polytherapy (p &lt; 0.01). ASM polytherapy and age were significant risk factors in regression models, but the explanatory value was low. The most common side effect was tiredness followed by cognitive symptoms. Our findings show that side effects are still common in epilepsy care and suggests that unnecessary polypharmacy should be avoided. Apart from number or ASMs, predicting who will experience side effects is difficult and more research on individual vulnerability is needed.</description><identifier>ISSN: 1059-1311</identifier><identifier>ISSN: 1532-2688</identifier><identifier>EISSN: 1532-2688</identifier><identifier>DOI: 10.1016/j.seizure.2023.10.016</identifier><identifier>PMID: 37931352</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Epilepsy ; Neurologi ; Neurology ; Side effects ; Treatment</subject><ispartof>Seizure (London, England), 2023-12, Vol.113, p.23-27</ispartof><rights>2023</rights><rights>Copyright © 2023. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c398t-9fdc560eb3681a7568c4a941bf2d2a3a01a90cb51eec9b790bbf1a4383a8a58b3</cites><orcidid>0000-0001-9445-4545 ; 0000-0002-8334-951X ; 0000-0001-6797-6348 ; 0000-0003-0243-7292 ; 0000-0003-3137-9386</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37931352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/330865$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Zelano, Johan</creatorcontrib><creatorcontrib>Nika, Olha</creatorcontrib><creatorcontrib>Asztely, Fredrik</creatorcontrib><creatorcontrib>Larsson, David</creatorcontrib><creatorcontrib>Andersson, Klara</creatorcontrib><creatorcontrib>Andrén, Kerstin</creatorcontrib><title>Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study</title><title>Seizure (London, England)</title><addtitle>Seizure</addtitle><description>•A study of patient-reported ASM side effects in a multicenter observational study.•A total of 40 % (05 %CI 36–45) out of 406 participants reported side effects.•The number of ASMs and age were significant risk factors for side effects.•Side effects remain a clinical concern. Side effects is one of the major clinical problems in epilepsy care. We assessed the prevalence of ASM side effects in participants in a large regional multicenter observational study in western Sweden and aimed to identify risk factors and inventory the nature of side effects with different ASM regimes. Cross-sectional analysis of survey answers and clinical characteristics of 406 adult participants recruited to a regional observational study between December 2020 and March 2023. Half of the participants had been seizure free for one year. Second-generation or newer ASMs were the most common. A total of 164 (40 %, 95 %CI: 36–45) patients reported side effects. Patients reporting side effects were younger (median 41 vs 47 years, p = 0.015), had more frequently experienced a seizure in the last year (p = 0.02), and were more often on ASM polytherapy (p &lt; 0.01). ASM polytherapy and age were significant risk factors in regression models, but the explanatory value was low. The most common side effect was tiredness followed by cognitive symptoms. Our findings show that side effects are still common in epilepsy care and suggests that unnecessary polypharmacy should be avoided. Apart from number or ASMs, predicting who will experience side effects is difficult and more research on individual vulnerability is needed.</description><subject>Epilepsy</subject><subject>Neurologi</subject><subject>Neurology</subject><subject>Side effects</subject><subject>Treatment</subject><issn>1059-1311</issn><issn>1532-2688</issn><issn>1532-2688</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkUuPEzEQhEcIxD7gJ4B85DLBHscT-4TQaoGVVgIJOFttuyc4mswMfmS1_Ho6StgrJ1vVn6vlqqZ5I_hKcNG_360yxj814arjnSRtReqz5lIo2bVdr_VzunNlWiGFuGiuct5xzs1ayJfNhdwYKaTqLpvDt4QHGHHyyGAKbIJCnmwe2AIl4lTahMucCgYal3jeyfYYoidgnliOARkOA_qSWZwYsO8PNM2_WMItATCyfR1LbD25YWK51PD4qnkxwJjx9fm8bn5-uv1x86W9__r57ubjfeul0aU1Q_Cq5-hkrwVsVK_9GugPbuhCBxK4AMO9UwLRG7cx3LlBwFpqCRqUdvK6aU---QGX6uyS4h7So50h2m1dLEnbajNaKbnuFfHvTvyS5t8Vc7H7mD2OI0w412w7rXsjN70yhKoT6tOcc8LhyVxwe6zI7uw5Lnus6CiTSu_enldURzE-vfrXCQEfTgBSMIeIyWYfjwWFmChkG-b4nxV_AWHDqKY</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Zelano, Johan</creator><creator>Nika, Olha</creator><creator>Asztely, Fredrik</creator><creator>Larsson, David</creator><creator>Andersson, Klara</creator><creator>Andrén, Kerstin</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope><orcidid>https://orcid.org/0000-0001-9445-4545</orcidid><orcidid>https://orcid.org/0000-0002-8334-951X</orcidid><orcidid>https://orcid.org/0000-0001-6797-6348</orcidid><orcidid>https://orcid.org/0000-0003-0243-7292</orcidid><orcidid>https://orcid.org/0000-0003-3137-9386</orcidid></search><sort><creationdate>20231201</creationdate><title>Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study</title><author>Zelano, Johan ; Nika, Olha ; Asztely, Fredrik ; Larsson, David ; Andersson, Klara ; Andrén, Kerstin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-9fdc560eb3681a7568c4a941bf2d2a3a01a90cb51eec9b790bbf1a4383a8a58b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Epilepsy</topic><topic>Neurologi</topic><topic>Neurology</topic><topic>Side effects</topic><topic>Treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zelano, Johan</creatorcontrib><creatorcontrib>Nika, Olha</creatorcontrib><creatorcontrib>Asztely, Fredrik</creatorcontrib><creatorcontrib>Larsson, David</creatorcontrib><creatorcontrib>Andersson, Klara</creatorcontrib><creatorcontrib>Andrén, Kerstin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Seizure (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zelano, Johan</au><au>Nika, Olha</au><au>Asztely, Fredrik</au><au>Larsson, David</au><au>Andersson, Klara</au><au>Andrén, Kerstin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study</atitle><jtitle>Seizure (London, England)</jtitle><addtitle>Seizure</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>113</volume><spage>23</spage><epage>27</epage><pages>23-27</pages><issn>1059-1311</issn><issn>1532-2688</issn><eissn>1532-2688</eissn><abstract>•A study of patient-reported ASM side effects in a multicenter observational study.•A total of 40 % (05 %CI 36–45) out of 406 participants reported side effects.•The number of ASMs and age were significant risk factors for side effects.•Side effects remain a clinical concern. Side effects is one of the major clinical problems in epilepsy care. We assessed the prevalence of ASM side effects in participants in a large regional multicenter observational study in western Sweden and aimed to identify risk factors and inventory the nature of side effects with different ASM regimes. Cross-sectional analysis of survey answers and clinical characteristics of 406 adult participants recruited to a regional observational study between December 2020 and March 2023. Half of the participants had been seizure free for one year. Second-generation or newer ASMs were the most common. A total of 164 (40 %, 95 %CI: 36–45) patients reported side effects. Patients reporting side effects were younger (median 41 vs 47 years, p = 0.015), had more frequently experienced a seizure in the last year (p = 0.02), and were more often on ASM polytherapy (p &lt; 0.01). ASM polytherapy and age were significant risk factors in regression models, but the explanatory value was low. The most common side effect was tiredness followed by cognitive symptoms. Our findings show that side effects are still common in epilepsy care and suggests that unnecessary polypharmacy should be avoided. Apart from number or ASMs, predicting who will experience side effects is difficult and more research on individual vulnerability is needed.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37931352</pmid><doi>10.1016/j.seizure.2023.10.016</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-9445-4545</orcidid><orcidid>https://orcid.org/0000-0002-8334-951X</orcidid><orcidid>https://orcid.org/0000-0001-6797-6348</orcidid><orcidid>https://orcid.org/0000-0003-0243-7292</orcidid><orcidid>https://orcid.org/0000-0003-3137-9386</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1059-1311
ispartof Seizure (London, England), 2023-12, Vol.113, p.23-27
issn 1059-1311
1532-2688
1532-2688
language eng
recordid cdi_swepub_primary_oai_gup_ub_gu_se_330865
source ScienceDirect Freedom Collection 2022-2024
subjects Epilepsy
Neurologi
Neurology
Side effects
Treatment
title Prevalence and nature of patient-reported antiseizure medication side effects in a Swedish regional multi-center study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T08%3A08%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20and%20nature%20of%20patient-reported%20antiseizure%20medication%20side%20effects%20in%20a%20Swedish%20regional%20multi-center%20study&rft.jtitle=Seizure%20(London,%20England)&rft.au=Zelano,%20Johan&rft.date=2023-12-01&rft.volume=113&rft.spage=23&rft.epage=27&rft.pages=23-27&rft.issn=1059-1311&rft.eissn=1532-2688&rft_id=info:doi/10.1016/j.seizure.2023.10.016&rft_dat=%3Cproquest_swepu%3E2886937659%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c398t-9fdc560eb3681a7568c4a941bf2d2a3a01a90cb51eec9b790bbf1a4383a8a58b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2886937659&rft_id=info:pmid/37931352&rfr_iscdi=true